HANGZHOU, China, Feb. 19, 2021 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. (Sciwind), a clinical-stage, fast-growing biopharmaceutical company focusing on research and development of innovative biologics, today announced the closing of an US$37 Million series B financing. The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.

Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials. A phase 1 clinical study of XW003, has been completed in an overseas clinical site, and phase 2 clinical trials including type II diabetes, obesity and non-alcoholic steatohepatitis (NASH), are expected to be initiated in China in 2021. Two more Investigational New Drug (IND) applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.

”Sciwind is now entering an exciting new era. We welcome the new investors and greatly appreciate the strong support of existing investors. The successful completion of series B financing shows the confidence of the investors in Sciwind team and R&D projects,” said Hai Pan, Ph.D., Sciwind’s founder and CEO. “The new investment will help to drive current clinical projects and push forward other First-in-Class/Best-in-Class drug candidates from our pipeline into clinical development. It also helps the expansion of our talent team and we hope to -attract more talents to join Sciwind team to provide patients with products of high clinical value and bring sustained financial return to the investors.”

Mr. Gang Chen, Partner at LYFE Capital, said “We are very pleased to be an investor and partner of Sciwind. LYFE Capital is committed to invest in biopharmaceutical companies with extraordinary management teams and great prospects. Sciwind stands out due to its strong R&D capability and highly experienced management team, which makes us very confident about the future of Sciwind. In addition to financial support, we will make every effort to provide Sciwind with more support, such as global partnerships, collaborations, regulatory guidance and local market access.”

Mr. Tan Hong, Managing Director at Legend Capital, said “Sciwind is one of the elite biopharmaceutical companies in China and its innovative and entrepreneurial culture has always impressed us. Since our last investment on Sciwind in 2019, we are delighted to see a series of progress achieved by Sciwind. We look forward to working closely with the talented team at Sciwind and other investors to improve patients’ quality of life”

About Sciwind Biosciences

Sciwind Biosciences is focusing on the therapeutic area of chronic metabolic and immunological diseases and devoted to research and development of global First- or Best-in-Class biologics. Sciwind owns multiple proprietary technologies, including oral peptide and inhaled protein therapeutics platforms. Sciwind establishes a series of R&D pipelines based on these core platform technologies. For more information, please contact us via pr@sciwind.com.cn.

About LYFE Capital

Founded in 2015, LYFE Capital is a dedicated healthcare fund with $1.3 billion in assets under management. LYFE Capital is actively seeking healthcare companies with exceptional management teams and expansive vision geared towards global markets. LYFE Capital focus spans biopharmaceuticals, medical devices, and diagnostics. LYFE Capital work closely with portfolio companies to support their needs by providing capital and active support in global partnerships, collaborations, regulatory guidance and local market access. At LYFE Capital，portfolio companies are not just investments, but rather long-term partners.

About Legend Capital

Legend Capital, founded in April 2001，is the independent Venture Capital investment subsidiary under Legend Holdings. In February 2012, Legend Capital took the new Chinese name “(Junlian)”. Legend Capital is now managing several USD funds and RMB funds with a total AUM RMB 50bn, and focuses on innovation and growth enterprises with operations in China or related to China. By 2020, Legend Capital has invested in over 500 companies, nearly 80 are successfully listed on domestic or overseas capital market, besides, more than 60 companies achieved exit through M&A.